| scholarly article | Q13442814 |
| P2093 | author name string | Y Yamamoto | |
| T Nomura | |||
| T Sugawara | |||
| Y Imai | |||
| Y Fujisawa | |||
| A Fujishima | |||
| P2860 | cites work | Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment | Q24561952 |
| MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures | Q26778412 | ||
| Crystal structure of papain-E64-c complex. Binding diversity of E64-c to papain S2 and S3 subsites | Q27642171 | ||
| The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity | Q27651464 | ||
| Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors | Q27730182 | ||
| Crystal structures of recombinant rat cathepsin B and a cathepsin B-inhibitor complex. Implications for structure-based inhibitor design | Q27730414 | ||
| Crystal structure of a papain-E-64 complex | Q34524433 | ||
| Crystal structure of an actinidin-E-64 complex | Q46521277 | ||
| Participation of cathepsin L on bone resorption | Q70670024 | ||
| Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells | Q71033250 | ||
| Characterization and crystallization of recombinant human cathepsin L | Q71829127 | ||
| Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis | Q72296654 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | crystal structure | Q895901 |
| P304 | page(s) | 47-50 | |
| P577 | publication date | 1997-04-21 | |
| P1433 | published in | FEBS Letters | Q1388051 |
| P1476 | title | The crystal structure of human cathepsin L complexed with E-64 | |
| P478 | volume | 407 |
| Q35683586 | 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents |
| Q89634052 | A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L |
| Q52534368 | Acidic pH as a physiological regulator of human cathepsin L activity. |
| Q55474273 | Affinity-Enhanced Luminescent Re(I)- and Ru(II)-Based Inhibitors of the Cysteine Protease Cathepsin L. |
| Q28262233 | Autocatalytic processing of recombinant human procathepsin L. Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro |
| Q73669332 | Beta-cyclodextrin/epoxysuccinyl peptide conjugates: a new drug targeting system for tumor cells |
| Q108502694 | Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development |
| Q33200667 | Cloning and characterization of a gut-specific cathepsin L from the aphid Aphis gossypii. |
| Q27617244 | Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. |
| Q42846520 | Crystal structure of human cathepsin S. |
| Q27748903 | Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function |
| Q26860406 | Cysteine cathepsins: from structure, function and regulation to new frontiers |
| Q43610411 | Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors |
| Q42001497 | Design, synthesis and biological evaluation of a library of thiocarbazates and their activity as cysteine protease inhibitors |
| Q74151522 | Development of peptidyl alpha-keto-beta-aldehydes as new inhibitors of cathepsin L--comparisons of potency and selectivity profiles with cathepsin B |
| Q34855069 | Dissecting the active site of the collagenolytic cathepsin L3 protease of the invasive stage of Fasciola hepatica. |
| Q35826183 | Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences |
| Q98721032 | Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2 |
| Q33920156 | Fractal intermediates in the self-assembly of silicatein filaments |
| Q30897474 | Highly potent inhibitors of human cathepsin L identified by screening combinatorial pentapeptide amide collections |
| Q41728795 | Identification and characterization of a cathepsin-L-like peptidase in Eimeria tenella |
| Q39035003 | Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor |
| Q40747704 | Identification, mRNA expression profiling and activity characterization of cathepsin L from red drum (Sciaenops ocellatus). |
| Q27315852 | In vivo imaging with fluorescent smart probes to assess treatment strategies for acute pancreatitis |
| Q77917014 | Inhibition of cysteine proteases by peptides containing aziridine-2,3-dicarboxylic acid building blocks |
| Q33327656 | Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L |
| Q26749121 | Lysosomal cathepsins and their regulation in aging and neurodegeneration |
| Q33857460 | Lysosomal cysteine proteases: more than scavengers |
| Q42611608 | Molecular and enzymatic properties of a cathepsin L-like proteinase with distinct substrate specificity from northern shrimp (Pandalus borealis). |
| Q43662638 | Molecular cloning and characterization of cathepsin L encoding genes from Fasciola gigantica |
| Q41889166 | Molecular docking of cathepsin L inhibitors in the binding site of papain |
| Q38551513 | Phage display selection can differentiate insecticidal activity of soybean cystatins |
| Q30848784 | Probing the specificity of cysteine proteinases at subsites remote from the active site: analysis of P4, P3, P2' and P3' variations in extended substrates. |
| Q41710645 | Proregion structure of members of the papain superfamily. Mode of inhibition of enzymatic activity |
| Q37053834 | Proteases for processing proneuropeptides into peptide neurotransmitters and hormones |
| Q28612038 | Proteolysis and antigen presentation by MHC class II molecules |
| Q41730414 | Revised definition of substrate binding sites of papain-like cysteine proteases |
| Q27664560 | Structural basis for reversible and irreversible inhibition of human cathepsin L by their respective dipeptidyl glyoxal and diazomethylketone inhibitors |
| Q24293301 | Structural basis for the recognition and cleavage of histone H3 by cathepsin L |
| Q73077056 | Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo |
| Q43601519 | Synthesis and hydrolysis by cathepsin B of fluorogenic substrates with the general structure benzoyl-X-ARG-MCA containing non-natural basic amino acids at position X. |
| Q36281760 | The N-terminal region of cystatin A (stefin A) binds to papain subsequent to the two hairpin loops of the inhibitor. Demonstration of two-step binding by rapid-kinetic studies of cystatin A labeled at the N-terminus with a fluorescent reporter group |
| Q73526016 | The high stability of cruzipain against pH-induced inactivation is not dependent on its C-terminal domain |
| Q42549117 | The prohormone proenkephalin possesses differential conformational features of subdomains revealed by rapid H-D exchange mass spectrometry |
| Q61066436 | aziridinyl peptides as inhibitors of cysteine proteases: Effect of a free carboxylic acid function on inhibition |
Search more.